Endo International PLC (NASDAQ:ENDP) (TSE:ENL) had its price objective trimmed by Cantor Fitzgerald from $9.00 to $7.00 in a report issued on Friday. The firm currently has a neutral rating on the stock.

Several other brokerages also recently commented on ENDP. Goldman Sachs Group, Inc. (The) started coverage on shares of Endo International PLC in a research report on Thursday, September 28th. They issued a sell rating and a $7.00 price target for the company. Royal Bank Of Canada reduced their price target on shares of Endo International PLC from $9.00 to $8.00 and set a sector perform rating for the company in a research report on Friday. Piper Jaffray Companies reiterated a hold rating and issued a $9.00 price objective on shares of Endo International PLC in a research note on Sunday, September 17th. Mizuho reiterated a buy rating and issued a $14.00 price objective (down previously from $19.00) on shares of Endo International PLC in a research note on Tuesday, September 12th. Finally, Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Endo International PLC in a research note on Tuesday, August 8th. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $11.67.

Shares of Endo International PLC (NASDAQ:ENDP) traded up $0.84 during trading hours on Friday, hitting $6.93. 12,136,900 shares of the company traded hands, compared to its average volume of 7,342,927. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 10.78. The stock has a market cap of $1,550.00, a P/E ratio of 1.43 and a beta of 0.53. Endo International PLC has a fifty-two week low of $5.77 and a fifty-two week high of $18.63.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.06. The business had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. Endo International PLC had a negative net margin of 126.97% and a positive return on equity of 66.98%. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.01 EPS. sell-side analysts predict that Endo International PLC will post 3.54 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Endo International PLC (ENDP) PT Lowered to $7.00 at Cantor Fitzgerald” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/endo-international-plc-endp-pt-lowered-to-7-00-at-cantor-fitzgerald/1701076.html.

In other news, CFO Blaise Coleman acquired 6,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The stock was acquired at an average cost of $7.89 per share, with a total value of $51,285.00. Following the acquisition, the chief financial officer now owns 13,729 shares in the company, valued at $108,321.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.50% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ENDP. James Investment Research Inc. bought a new stake in shares of Endo International PLC during the 2nd quarter worth $113,000. Blair William & Co. IL bought a new stake in shares of Endo International PLC during the 2nd quarter worth $126,000. LMR Partners LLP bought a new stake in shares of Endo International PLC during the 3rd quarter worth $148,000. Point View Wealth Management Inc. boosted its holdings in shares of Endo International PLC by 16.6% during the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after buying an additional 1,900 shares during the period. Finally, Riverhead Capital Management LLC boosted its holdings in shares of Endo International PLC by 64.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after buying an additional 5,887 shares during the period. 90.50% of the stock is owned by institutional investors and hedge funds.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.